Podcasts about Davide

Bentornati e bentornate su Azure Italia Podcast, il podcast in italiano su Microsoft Azure!Per non perderti nessun nuovo episodio clicca sul tasto FOLLOW del tuo player

In questa video intervista approfondiamo il percorso umano e professionale di Davide D'Errico, fotografo e docente che da anni combina creatività, competenza tecnica e capacità comunicativa. Davide ci racconta come nasce la sua passione per l'immagine, l'evoluzione del suo stile fotografico e il ruolo fondamentale della luce, dell'attesa e dello sguardo nel costruire uno scatto capace di emozionare.Accanto all'attività artistica, Davide dedica gran parte del suo tempo alla formazione, trasmettendo ai suoi studenti non solo tecniche e strumenti, ma soprattutto una visione consapevole della fotografia come linguaggio.Parliamo dei suoi metodi didattici, delle sfide dell'insegnamento, dei progetti che lo hanno segnato e di come accompagnare le nuove generazioni in un percorso fotografico autentico.Sigla (Voce): Mara Rechichigiovannicertoma.it

Fosse can finally touch the ground, go for a walk and meet other dog friends - I also get to go on an unexpected trip to London and I reveal Davide's Spotify Unwrapped

What do classical music, vintage motorcycles, brambles, indulgent flavours and The Glendronach have in common…?… They're all things Rachel Barrie loves – and you can definitely feel that in this brand-new episode of “The Barrel Talk”.For the episode with Rachel, Miri teamed up with Davide, better known as @whisky_munich on Instagram, while Martin and Manu are taking a break this time.Rachel Barrie is a woman who does not need much introduction. She's a legend in the whisky industry and the master blender of The Glendronach, so we were thrilled, when the opportunity arose to meet her for a chat in our hometown Munich. You can feel from the very start how much Rachel loves being Glendronach's master blender because for her, it is a perfect opportunity to combine the affection for her hometown with the art and science of creating great whisky (such as the stunning, new 40-year-old).There was so much to talk about, ranging from Rachel's love for whisky from early on to insights into the whisky industry after having worked in it for decades, and from Glendronach's history to applying her knowledge about maturation and whisky-making to create “the ultimate sherry cask indulgence”.So pour your favourite dram and don't miss out on this absolutely “brambleous” episode.

Cosa significa che il computer e' nostro e ci dobbiamo poter mettere quello che vogliamo ?Ecco. Per Apple non e' cosi'. FSFE davanti alla Corte di Giustizia Europea arringa (un avvocato contro 10 di Apple) a difesa degli sviluppatori.Davide contro Golia.Per dire che se i giocattoli possono essere limitati per motivi di sicurezza, anche i sistemi operativi possono essere sbloccati per difendere la libertà dei cittadini europei.Passo falso ingenuo di Apple ? Dalle date forse solo un eccesso di sicurezza del team legale.Il testo tradotto in italiano in area riservata.Da parte mia e di tutti gli ascoltatori … grazie a Davide per avermi mandato i file audio (intro e outro) migliorati !

Franklin David e Vitor Vianna revelam os melhores e piores destinos para viajar em 2026. Quer saber quais lugares são os mais baratos e que você não vai passar perrengue? Assista ao conteúdo do Eles que Lutem até o final e confira o guia de viagem dos Aventureiros! #viagem #aventureiros #guiadeviagem

Davide De Pierro is a New Jersey native that has cultivated over 2.7M followers on TikTok and 2.1M followers on Instagram and has been earning millions of views online. The author of his newly released novel, The Letters I Never Sent, Davide is known for his commentary on the everyday moments that capture the human experience. Davide's storytelling in his content and his novel blends raw humor and relatable honesty to explore modern love, identity, and the beautiful mess of being human. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Guests Dr. Andrea Necchi, Dr. Ashish Kamat and host Dr. Davide Soldato discuss JCO article "End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer," focusing on the evolving treatment landscape of MIBC (muscle-invasive bladder cancer) and the need to properly design novel trials investigating non-operative management while including the incorporation of biomarkers and patient perspectives in clinical trials. TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Dr. Davide Soldato: Hello and welcome to JCO After Hours, the podcast where we sit down with authors from some of the latest articles published in the Journal of Clinical Oncology. I am your host, Dr. Davide Soldato, medical oncologist at Ospedale San Martino in Genoa, Italy. Today we are joined by JCO authors Andrea Necchi, Associate Professor of Medical Oncology at University San Raffaele and Medical Oncology at Ospedale San Raffaele in Milan, Italy, and Ashish Kamat, Professor of Urologic Oncology and Cancer Research at University of Texas MD Anderson Cancer Center. Both Professor Necchi and Professor Kamat are internationally recognized experts in the field of genitourinary malignancy and particularly in bladder cancer. Today we will be discussing the article titled "Endpoints for the Next Generation Bladder-Sparing Perioperative Trials for Patients with Muscle-Invasive Bladder Cancer." So thank you for speaking with us, Professor Necchi and Professor Kamat. Dr. Andrea Necchi: Thank you, Davide, and thank you JCO for the opportunity. Dr. Ashish Kamat: Yeah, absolutely. It is a great honor and privilege to be discussing this very important article with you. So thank you for the invitation. Dr. Davide Soldato: The article that you just published in JCO reports the results of a consensus meeting that was held among experts in the field of genitourinary malignancy and particularly for bladder cancer. So the objective was really to define endpoints for a novel generation of trials among patients diagnosed with muscle-invasive bladder cancer. So my first question would be: what is the change in clinical practice and in clinical evidence that we have right now that prompted the start of such consensus in 2025? Dr. Andrea Necchi: So, we are living so many changes in the treatment paradigm of patients with muscle-invasive bladder cancer. In general, patients diagnosed with bladder cancer or urothelial cancer today, thanks to the advent of immunotherapy or immunotherapy combinations, and today thanks to the advent of novel antibody-drug conjugates like enfortumab vedotin in combination with immunotherapy that are actually changing the landscape of treatment of patients with metastatic disease and also are entering quite fast into the treatment paradigm of patients with organ-confined disease with a lot of clinical trials testing these combination therapies, neoadjuvantly or adjuvantly, before or after radical cystectomy. Having said that, by potentiating the efficacy of systemic therapy, an increasing number of patients that receive neoadjuvant therapy of any kind, at a certain point in time, result to have achieved a deep response to systemic therapy, evaluated radiologically with conventional imaging, CT scan or MRI, or with cystoscopy or with other urology-based techniques, urinary cytology, and so. And based on the fact that they achieve a complete response, so no residual viable disease after systemic therapy, they raise concern about the fact that they have to undergo surgery like radical cystectomy that is quite impactful for their quality of life and for the future of their lives after the surgery. So the point that the patients are raising, and the patients are raising this point, is primarily due to the efficacy of systemic therapy. And we have seen so many cases fortunately achieving a deep response. So the question about what to do with the patient that at a certain point, at the start with the commitment to radical cystectomy, but at a certain point in time change their mind towards something else if possible, depending on the fact that they have achieved a deep response, is something that is a question and is a need to which we have to provide data, information, and guidance in general to the patients. Dr. Davide Soldato: If we look at the population that the recommendations were formulated for, we are mainly speaking about patients who would be fit for cystectomy, and this is a very distinct population compared to those who are not fit for cystectomy, both from a medical oncology point of view but also from a urologic point of view in terms of surgery. So, can you explain a little bit to our listeners why you think that this distinction is critical and why you developed this recommendation especially for this population? Dr. Ashish Kamat: That is a very important distinction that you made. To build upon what Professor Necchi mentioned earlier, this question that we get from patients after neoadjuvant therapy or systemic therapy is not a new question. It has been something that they have been asking us for the last 20 or 30 years. "Do I really need to have my bladder taken out?" And patients who are especially not fit for surgery will sometimes say, "Do I need to have my bladder taken out? And if I cannot have my bladder taken out, am I going to just not have anything done?" Because the eligibility for radical cystectomy is also a moving target. Over the years with improvement in surgical technique, improvement in perioperative therapy, ERAS protocols, et cetera, it is really unusual for us to deny a patient the opportunity to have major surgery unless clearly they have very significant comorbid conditions. So I think this endeavor is more broadly encompassing of the patient population than what was evident in previous years. And I really want to give a shout out to Professor Necchi because what we did was, as part of the International Bladder Cancer Group and Professor Necchi is an integral part of the scientific advisory board, we broached this topic broadly during one of our discussions. And of course, Andrea always does this, he picks on a topic and then he says, "Okay, we need to discuss this really in detail," put together a multinational, multicenter collaborative group, but the driving force was our patients. Because our patients are constantly asking, "Do I need to lose my organ? Do I need to have radiation therapy?" which again, also, has a lot of side effects. So this was really to answer the question in today's day and age as to do we need to do local consolidation, and if so, in what way? It is not a new question, but we have newer therapies, newer technology, and better ways to answer this. So it is a much needed question that needs to be answered. And I think the distinction between non-surgical candidates and surgical candidates is a little bit blurred in today's day and age. Dr. Davide Soldato: What about the eligibility, for example, for cisplatin-based chemotherapy? Because I think that that is a very fundamental part of this type of strategy that we apply to patients with muscle-invasive bladder cancer. So we know that there are some caveats for proposing such treatment. And also this population was specifically defined inside this recommendation. Dr. Andrea Necchi: I think that the focus of our work is just to analyze what is happening after any type of systemic therapy the patient may get neoadjuvantly. So it is not actually a question of treatment eligibility or including cisplatin eligibility. This is an old question of today's practice and clinical trials. But regardless of what the patient received neoadjuvantly, the point that we have addressed in our consensus meeting was what to do next as a further step after systemic therapy or not. So basically we are- the consensus guidance includes all-comers, so patients to get any type of systemic therapy. So really non-selected based on specific features that determine a special eligibility to a special or a particular therapy. But an all-comer approach is always the winning approach for the translation to be in practice, an all-comer approach just focusing on what has happened after treatment and that we are assessing by the use of conventional imaging, MRI or CT, cystoscopy, urinary cytology, and trying to merge all together this information, all these features in a unique, shared, reliable definition of clinical complete response that could be used as a biomarker for the selection of newer therapies instead of pathological response that has been historically used, and maybe surrogate for the outcome, the long-term outcome and survival of these patients. Dr. Davide Soldato: A very specific point of the consensus was actually the definition of clinical complete response. As you were saying, this is actually a combination of several parameters including urinary cytology, the use of cross-sectional imaging, for example CT scan, but also the evaluation in cystoscopy of the bladder. Do you foresee any potential problems when applying this type of recommendation, not inside clinical trials, but in the context of routine clinical practice? Dr. Ashish Kamat: Absolutely. And that was the whole reason we had this consensus meeting. What happens nowadays in daily practice, and we see this every day at our center, we see patients referred to us. This definition or this sort of attempt to define clinical complete response is an ongoing issue. And urologists, medical oncologists, radiation oncologists are always looking to see, does my patient have a complete response? That definition and those paradigms have changed and evolved over the years. The FDA had a workshop many years ago looking at this very question. And it was to address the proposal that complete clinical response, which is a clinical definition, a clinical state, does this correlate with pathologic response? And with the technology and the systemic therapies we had then, the answer was 'no'. In fact, more patients got recurrent disease than did not get recurrent disease. And that is why, of course in the paper we mention the trials that looked at this question, the trials that evolved around this question. And I think the distinction between a clinical trial and daily practice is extremely important when we are looking at this definition per se. Because essentially what happens with this issue is that if the patient is not appropriately counseled, and if the physician does not do the appropriate clinical complete response assessment as Professor Necchi mentioned, right, cystoscopy, cytology, imaging, use of markers that are still in evolvement, we risk doing harm to the patient. So we caution in the paper too that this definition is not ready for prime time use. It is something that needs to be studied. It is a rigorous definition and currently we are recommending it for clinical trials. I am sure eventually it will trickle down into clinical practice, but that guidance was not the purpose of this consensus meeting. Dr. Davide Soldato: There are several parameters that are potentially evolving and could potentially enter inside of clinical practice. For example, you mentioned pelvic MRI and we have now very specific criteria, the VI-RADS criteria, we're able actually to diagnose and also to provide information. So along with these novel imaging techniques, we also know that there are novel biomarkers that could be explored, for example ctDNA and urinary DNA. So what I was wondering is, why were not these included inside the definition that you provide for clinical complete response? And do you think that, as we are designing these trials to potentially spare cystectomy for this patient, we should include these biomarkers very early so that we can actually provide better stratification for our patients and really propose this type of cystectomy-sparing strategy only to those where we are very confident that we have obtained a clinical complete response? Dr. Andrea Necchi: I would say you have just to wait. So a follow-up is ongoing and hard work is ongoing. At the time we met, at the time we established the meeting in mid-December last year, we had no information on the ctDNA data from major trials, with only a few exceptions. So we were just at the beginning of a story that was more than likely to change but still without numbers and without data from clinical trials. Now in just nine months or 10 months time, we have accumulated important data and newer data will be presented during just a few weeks and a few days regarding the ctDNA, circulating tumor DNA in particular, as a prognostic marker assessed baseline or assessed after neoadjuvant therapy. So the point is certainly well made and ctDNA is certainly well shaped to be incorporated in a future definition of clinical complete response. But you have to consider the fact that most of the data that we are accumulating related to ctDNA are about the post-cystectomy field or the metastatic field. So regarding neoadjuvant therapy, you know, we have neoadjuvant therapy in the context of bladder-sparing approach, basically we have no information. And the point that is emerging in our daily practice when using these biomarkers or in clinical trials, and the impression in general, is that it is a very strong biomarker associated with survival, but we absolutely do not know what is the performance of the test in the prediction of superficial bladder relapses, high-grade pTa relapse in the bladder that is left untouched in the patient. We are considering, and maybe it will be just a matter of further discussion, not just what is happening within the immediate endpoint of clinical CR, but also what is happening later with other survival endpoints. And for example, when looking at the type of events that we may see in this kind of bladder-sparing approaches, most of the events, also in the trials that have been published including the RETAIN study published in JCO, most of the events are related to superficial high-grade superficial non-muscle invasive relapses. So the ability to predict these types of events with ctDNA is completely unknown. Maybe, maybe other liquid biomarkers like urinary tumor DNA, utDNA, could be a bit better shaped in the prediction of this kind of events, you know. But we have still to build the story. So the question is good. The answer is yes, we will likely, more than likely incorporate liquid biomarkers in the definition, but we have to wait at least more data and more robust data in order to translate this information in routine practice, you know. Another consensus meeting is organized by IBCG and the same folks for November. This meeting will be primarily focused on the liquid biomarkers, the interpretation and use and approval and so of liquid biomarkers including bladder cancer. And we will likely be able to address all these, most of these open issues, so most of these points in the next meetings. Dr. Davide Soldato: In the consensus you say that probably clinical complete response is now ready to be included in early phase trials, so actually to test what is the efficacy of the regimens that is being evaluated inside of these trials. But you actually do very in-depth work of defining what are the most appropriate endpoints for later phase trials. So to be very specific, the phase three registrational trials that bring new regimens inside of this space. So I just wanted to hear a little bit about what was the definition for event-free survival, which you define as the most appropriate one for this type of trials. And as you were mentioning before, Professor Necchi, there is a very specific interest on the type of events that we observe, especially when we look at these superficial relapses inside of the bladder. So was this a very urgent matter of debate as we define which type of events should actually trigger event-free survival? And did you make a very thoughtful decision about why using this type of endpoint instead of others, for example metastasis-free survival? Dr. Ashish Kamat: Yeah, this was a matter of intense debate as you might imagine. And again, this is a moving target. So as Professor Necchi mentioned, we tend to partner with each other, our organizations, on having definitions of clinical complete response, biomarker, retreats, and then using that as a marker, and you might imagine this definition of what is appropriate event-free survival, what events matter to the patient, is something we have been talking about for two years. It was not just something that came up at the retreat. But at the retreat there was intense discussion. One of the things that we talked about was bladder-intact event-free survival because we are trying to spare the patient's bladder. And do we count bladder-intact event-free survival as something that is relevant? The patient advocates absolutely liked that, right? They wanted that. But then we also learned from some of the studies, for example from the RETAIN study, that the non-muscle invasive recurrences can actually lead to metastatic disease. It is not as benign when you have a patient with muscle-invasive bladder cancer that then develops a non-invasive tumor because maybe there is cancer growing underneath the surface that we don't detect when we look in the bladder. So a lot of those discussions were held, debated. It was a consensus. I have to say it was not 100% agreement on that particular definition, but it was broad consensus. And Andrea, do you want to clarify a little bit as to how we came about that consensus? Because I think this is a very important point we need to make. Dr. Andrea Necchi: We focused on a bit different definition of BI-EFS, Bladder-Intact Event-Free survival. Just stating EFS as an all-inclusive parameter including all type of high-grade relapse or progression or death that may happen to the patient. So that we were counting high-grade pTa, pT1, CIS relapses to the bladder and of course more deeper involvement in the muscle layer and so, and metastatic disease as a relapse. But the point is that as compared to the classical bladder-intact EFS definition of chemoradiation bladder-sparing approaches that is including muscle-invasive relapses only or death as events, we tried to be as inclusive as possible in order to be as much conservative as possible and to raise as higher the bar as possible for the success. And this is actually what the patients are asking us. So they are asking, "Okay, I can save my bladder, sparing radical cystectomy, but at which cost?" So in order to provide an answer, we have to be very, very cautious and be on the right shape, on the right position to say, "Okay, we have accomplished the most, the safest points, you know, by which you can proceed with the bladder-sparing." This is the first point. The other point is related to the MFS, metastasis-free survival that you have mentioned. For sure, it was recognized as a very important point for sure. But in the discussion was clear that our focus was in saving patients, curing the patient, and saving the bladder. Any single event, superficial event that may occur in the bladder-saving approaches of this kind may expose the patient to an extra risk of developing distant metastases, as it happened for example in the RETAIN study. So EFS defined as we have agreed and published, is actually a way of including or anticipating in a safest position the MFS. Because most or if not the entirety of the events of metastasis development in patients undergoing bladder-sparing after neoadjuvant systemic therapy were preceded by a superficial phase of disease relapse, you know. So I remember very, very few, or we can count just on the finger of one hand, the cases that have been reported in the literature developing de novo metastatic disease in the similar bladder-sparing approaches, in particular when using a maintenance immunotherapy strategy, you know, after they reach TURBT. So this is the reason why with all the limitation that Ashish has mentioned, with all the uncertainties that are still there, the nervousness that is still there, EFS, as defined in the protocol, as put in the paper, is to us at the moment is the safest way to use a primary endpoint in potentially registration trials of this kind with perioperative systemic therapy and response-adapted surgery. Dr. Ashish Kamat: And David, just to be absolutely clear for our listeners, right, so what was the event-free survival that we defined? Essentially it was a very inclusive definition. Event was defined as high-grade tumor persistence, recurrence, or progression during or after perioperative therapy, and receipt of any additional standard of care treatment including radical cystectomy, radiotherapy or even intravesical therapy. So this was done at the behest of our patient advocates because we really wanted to make a very robust definition that could be utilized appropriately as an adequate primary endpoint for both early and late phase bladder preservation trials. Dr. Davide Soldato: I think that it really highlights one of the points that I liked the most about this consensus is that it really incorporated the patient vision and a sort of shared decision making process when we are deciding how we want to design these trials that will explore this bladder-sparing surgery. And Professor Necchi mentioned something that I think will be also a very interesting question for trials that will be developed considering the activity of this combination that we are seeing right now, which is maintenance. Because right now our approach in the few cases where patients do not do any type of treatments after an induction with neoadjuvant treatments is basically represented by observation. So I was wondering if you think that the field will actually evolve to a sort of maintenance strategy even in patients that will achieve a complete clinical response? Dr. Andrea Necchi: We just mentioned briefly in the paper, this is a very important point that was touched during the discussion, and in particular was raised and discussed by FDA people participating in the meeting. And when looking at the data from the trials that were available and are still available thus far, we could provide a suggestion that maintenance immune therapy is the preferred approach in this kind of approach as it currently stands, as the data currently stand. Because the cleanest data towards the successful part of this journey is related to the studies that provided a kind of maintenance therapy, like the study with nivolumab or the RETAIN-2 study with maintenance immune therapy instead of RETAIN study that was just stopping treatment until surgery with MVAC chemotherapy. So in general the impression is that maintenance therapy may help in reducing the type of events, including the events that we incorporate in the EFS definition that we mentioned in the paper. The point that you mentioned is very important because on the other side we have a problem, a big problem of affordability and cost of the treatment. The de-escalation trials are an urgent need and represent a call for the studies. Unfortunately, as you mentioned, this is something that moves beyond the possibilities of this type of consensus because we don't have data and we have to accumulate data from clinical trials prior to saying, "Okay, certain patients could de-escalate therapy and stop therapy and some other not." So we are still at the very beginning. So we can do- we can discuss about this in the radical cystectomy paradigm but not in the bladder-sparing paradigm, you know. But this is for sure a point, a discussion point that will be taken, pretty well taken in one year or two year projection. Dr. Davide Soldato: I was wondering if in the consensus, considering that patient advocates and patient associations were also involved, did you decide to actually suggest the inclusion of patient-reported outcomes or the evaluation of shared decision-making in the development of this trial really as endpoints that should matter as much or as much as possible as event-free survival and clinical complete response? Dr. Ashish Kamat: Oh yeah, absolutely. We had patient advocates, we had the World Bladder Cancer Patient Coalition, Bladder Cancer Advocacy Network, patient representatives. And we always consider this. Shared decision-making is actually the impetus behind why these efforts have been launched, right? So it is the shared decision-making that is very, very important. It is the driving force behind what we do. And it is worth noting, for example, for the design of such studies, regulatory agencies consider response-based endpoints or overall survival as primary endpoints. But the patient advocates consider quality of life to be just as important, if not more important sometimes than overall survival numbers. Because patient advocates will say, "Well if I live longer but I'm miserable living longer, yes that works for regulatory agencies but doesn't work for us." So PROs clearly are very, very important. And, in fact, we just literally had a meeting in Houston, the IBCG meeting where PROs were a main point of what we discussed. So incorporating PROs in everything we do, not just this but everything we do, Dr. Necchi, myself, everybody involved in these fields realizes it is very, very important. So absolutely. Dr. Davide Soldato: I want to thank again Professor Necchi and Professor Kamat for joining us today. Dr. Andrea Necchi: Thank you. Dr. Ashish Kamat: It is our pleasure. Dr. Davide Soldato: Thanks again and we appreciate you sharing more on your JCO article titled "Endpoints for the Next Generation Bladder-Sparing Perioperative Trials for Patients with Muscle-Invasive Bladder Cancer." If you enjoy our show, please leave us a rating and review and be sure to come back for another episode. You can find all ASCO shows at asco.org/podcast. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

In the latest WSITH @talknorthpod, @russohockey and @anthonylapanta talk #mnwild (and Russo) travel problems, the Wild's 2-2 road trip, another elite Brodin effort vs. McJesus and producer Davide joins to talk Italian wine. Next live show: Dec. 15 at 7 p.m. at Tuttle's   from Aquarius Home Services Studio (www.aquariushomeservices.com) Supported by: Aquarius Home Services (www.aquariushomeservices.com/) Royal Credit Union (www.rcu.org/) Twill Edina Galleria  OnX Maps (www.onxmaps.com/) Clamshell Beach Resort (www.cottagesonwhitefish.com/) Stretchlab (www.stretchlab.com)

11 - Davide De Luca - Detto,scritto,fatto (Matthew Dee Nu Funk Remix) by Dj Teo Verona Official

14 - Davide Shorty - Non Si Mangia Una Canzone (Matthew Dee Nu Funk Remix) by Dj Teo Verona Official

Elvio Arrigucci Dio ci porta oltre i nostri limiti • Matteo 10: 2-3 • Marco 3 :17-18 • Luca 6: 14-15 • Giovanni 11 :16 • Giovanni 14: 5 • Giovanni 20: 24(27-28) • Giovanni 21: 2 Davide Raier La calma della fede • Marco 4: 35-41 • Isaia 30: 1-5 • Ebrei 11: 1 • Giacomo 1: 22 • Giovanni 4: 34 • 1 Giovanni 5 :4 Domenico Scutifero La vita di Davide e Salomone • 2 Samuele 22: 1-8 • 2 Samuele 22: 17-18 • 2 Cronache 7: 11-22 • 1 Re 11: 1-13 • Ecclesiaste 12: 1-10 Massimo Innaimi Affrontare le difficoltà di ogni giorno con fede e forza • Salmo 23: 4 • Geremia 17 :7 • Matteo 6: 34 • Romani 8: 28 --Guarda Canale 245 | Tivùsat 454 | Sky 854Scopri di più su www.paroledivita.org/linkinbio

In quel tempo, l'angelo Gabriele fu mandato da Dio in una città della Galilea, chiamata Nàzaret, a una vergine, promessa sposa di un uomo della casa di Davide, di nome Giuseppe. La vergine si chiamava Maria. Entrando da lei, disse: «Rallégrati, piena di grazia: il Signore è con te». A queste parole ella fu molto turbata e si domandava che senso avesse un saluto come questo. L'angelo le disse: «Non temere, Maria, perché hai trovato grazia presso Dio. Ed ecco, concepirai un figlio, lo darai alla luce e lo chiamerai Gesù. Sarà grande e verrà chiamato Figlio dell'Altissimo; il Signore Dio gli darà il trono di Davide suo padre e regnerà per sempre sulla casa di Giacobbe e il suo regno non avrà fine». Allora Maria disse all'angelo: «Come avverrà questo, poiché non conosco uomo?». Le rispose l'angelo: «Lo Spirito Santo scenderà su di te e la potenza dell'Altissimo ti coprirà con la sua ombra. Perciò colui che nascerà sarà santo e sarà chiamato Figlio di Dio. Ed ecco, Elisabetta, tua parente, nella sua vecchiaia ha concepito anch'essa un figlio e questo è il sesto mese per lei, che era detta sterile: nulla è impossibile a Dio». Allora Maria disse: «Ecco la serva del Signore: avvenga per me secondo la tua parola». E l'angelo si allontanò da lei.

Dal Vangelo secondo Luca (1,26-38)Al sesto mese, l'angelo Gabriele fu mandato da Dio in una città della Galilea, chiamata Nàzaret, a una vergine, promessa sposa di un uomo della casa di Davide, di nome Giuseppe. La vergine si chiamava Maria. Entrando da lei, disse: "Rallégrati, piena di grazia: il Signore è con te".A queste parole ella fu molto turbata e si domandava che senso avesse un saluto come questo. L'angelo le disse: "Non temere, Maria, perché hai trovato grazia presso Dio. Ed ecco, concepirai un figlio, lo darai alla luce e lo chiamerai Gesù. Sarà grande e verrà chiamato Figlio dell'Altissimo; il Signore Dio gli darà il trono di Davide suo padre e regnerà per sempre sulla casa di Giacobbe e il suo regno non avrà fine".Allora Maria disse all'angelo: "Come avverrà questo, poiché non conosco uomo?". Le rispose l'angelo: "Lo Spirito Santo scenderà su di te e la potenza dell'Altissimo ti coprirà con la sua ombra. Perciò colui che nascerà sarà santo e sarà chiamato Figlio di Dio. Ed ecco, Elisabetta, tua parente, nella sua vecchiaia ha concepito anch'essa un figlio e questo è il sesto mese per lei, che era detta sterile: nulla è impossibile a Dio". Allora Maria disse: "Ecco la serva del Signore: avvenga per me secondo la tua parola". E l'angelo si allontanò da lei.

In questa puntata di Office of Cards, Davide intervista Pasquale Acampora, un ospite che incarna perfettamente il concetto di carriera non lineare, crescita professionale e curiosità come bussola personale. Pasquale condivide un percorso insolito: dal sogno di diventare pilota, a una facoltà scelta quasi per caso, fino alla consulenza strategica. La sua storia dimostra che a volte non è la strada a scegliere noi, ma siamo noi a costruirla mentre la percorriamo.

Welcome back to Private Parts: This week Davide & Leigh are on the sofa this week to talk us through their whirlwind marriages, off camera chaos and who is still together! Plus they address all the latest rumours and what we can expect from the reunion!Make sure you subscribe and follow for more!

Welcome back to Private Parts: This week Davide & Leigh are on the sofa this week to talk us through their whirlwind marriages, off camera chaos and who is still together! Plus they address all the latest rumours and what we can expect from the reunion!Make sure you subscribe and follow for more!

On March 20th, 1995, the Tokyo subway system was flooded with sarin nerve gas in a coordinated terrorist attack by the religious cult Aum Shinrikyō. Led by the charismatic new-age guru, Shoko Asahara, the well-funded and technologically ambitious Aum organization manufactured and deployed chemical weapons in an attempt to bring about the end of the world. In the chaos that followed, 13 people were killed, thousands were injured, and the international community shuddered at the possibility of future attacks by fringe political groups.    SOURCES: Amarasingam, A. (2017, April 5). A history of sarin as a weapon. The Atlantic.  Cotton, Simon. “Nerve Agents: What Are They and How Do They Work?” American Scientist, vol. 106, no. 3, 2018, pp. 138–40.  Danzig, Richard; Sageman, Marc; Leighton, Terrance; Hough, Lloyd; Yuki, Hidemi; Kotani, Rui; Hosford, Zachary M.. Aum Shinrikyo: Insights Into How Terrorists Develop Biological and Chemical Weapons . Center for a New American Security. 2011. Gunaratna, Rohan. “Aum Shinrikyo's Rise, Fall and Revival.” Counter Terrorist Trends and Analyses, vol. 10, no. 8, 2018, pp. 1–6.  Harmon, Christopher C. “How Terrorist Groups End: Studies of the Twentieth Century.” Strategic Studies Quarterly, vol. 4, no. 3, 2010, pp. 43–84. JSTOR, http://www.jstor.org/stable/26269787.  “IHT: A Safe and Sure System — Until Now.” The New York Times, 21 Mar. 1995. Jones, Seth G., and Martin C. Libicki. “Policing and Japan's Aum Shinrikyo.” How Terrorist Groups End: Lessons for Countering al Qa'ida, RAND Corporation, 2008, pp. 45–62.  Kaplan, David E. (1996) “Aum's Shoko Asahara and the Cult at the End of the World”. WIRED.  Lifton, Robert Jay. Destroying the World to Save It: Aum Shinrikyo, Apocalyptic Violence, and the New Global Terrorism. 1999. Murakami, Haruki. Underground: The Tokyo Gas Attack and the Japanese Psyche. Translated by Alfred Birnbaum and Philip Gabriel. 2001. Murphy, P. (2014, June 21). Matsumoto: Aum's sarin guinea pig. The Japan Times.  Reader, Ian. Religious Violence in Contemporary Japan: The Case of Aum Shinrikyo.  2000. Tucker, Jonathan B. “Chemical/Biological Terrorism: Coping with a New Threat.” Politics and the Life Sciences, vol. 15, no. 2, 1996, pp. 167–83.  Ushiyama, Rin. “Shock and Anger: Societal Responses to the Tokyo Subway Attack.” Aum Shinrikyō and Religious Terrorism in Japanese Collective Memory., The British Academy, 2023, pp. 52–80.  Learn more about your ad choices. Visit megaphone.fm/adchoices

In quel tempo, mentre Gesù si allontanava, due ciechi lo seguirono gridando: «Figlio di Davide, abbi pietà di noi!». Entrato in casa, i ciechi gli si avvicinarono e Gesù disse loro: «Credete che io possa fare questo?». Gli risposero: «Sì, o Signore!». Allora toccò loro gli occhi e disse: «Avvenga per voi secondo la vostra fede». E si aprirono loro gli occhi. Quindi Gesù li ammonì dicendo: «Badate che nessuno lo sappia!». Ma essi, appena usciti, ne diffusero la notizia in tutta quella regione.

Dal Vangelo secondo MatteoIn quel tempo, mentre Gesù si allontanava, due ciechi lo seguirono gridando: «Figlio di Davide, abbi pietà di noi!».Entrato in casa, i ciechi gli si avvicinarono e Gesù disse loro: «Credete che io possa fare questo?». Gli risposero: «Sì, o Signore!».Allora toccò loro gli occhi e disse: «Avvenga per voi secondo la vostra fede». E si aprirono loro gli occhi.Quindi Gesù li ammonì dicendo: «Badate che nessuno lo sappia!». Ma essi, appena usciti, ne diffusero la notizia in tutta quella regione.

Vorresti ricevere notizie, saluti, auguri dalle Apostole della Vita Interiore?Lasciaci i tuoi contatti cliccando il link qui sotto e con la nostra nuova rubrica digitale potremo raggiungerti.https://www.it.apostlesofil.com/database/- Premi il tasto PLAY per ascoltare la catechesi del giorno e condividi con altri se vuoi -+ Dal Vangelo secondo Luca +In quel tempo, mentre Gesù si allontanava, due ciechi lo seguirono gridando: «Figlio di Davide, abbi pietà di noi!».Entrato in casa, i ciechi gli si avvicinarono e Gesù disse loro: «Credete che io possa fare questo?». Gli risposero: «Sì, o Signore!».Allora toccò loro gli occhi e disse: «Avvenga per voi secondo la vostra fede». E si aprirono loro gli occhi.Quindi Gesù li ammonì dicendo: «Badate che nessuno lo sappia!». Ma essi, appena usciti, ne diffusero la notizia in tutta quella regione.Parola del Signore.

In this solo episode, I'm answering your questions! From introducing Toto the other dogs, to why I refuse to engage in toxic political conversations, to the wild, honest truth about how I manifested Davide into my life. I also touch on how this idea of "feminism" can actually preventing you from finding your partner. I discuss how I shifted my mindset, got clear on what I wanted, became rooted in the ground, and was calling him in whie absolutely living my best life. Enjoy!Produced by Dear MediaSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Davide Talucci presenta "Pura follia" negli studi di Delta 1 con Daniele Di Ianni.

Primo appuntamento del nostro podcast Cineguru Extra da Sorrento: Andrea Francesco Berni e Gabriele Niola parlano della presentazione del listino di The Walt Disney Company, che ha aperto l'edizione 2025 delle Giornate Professionali con un roster davvero ricchissimo: da Avatar: Fuoco e Cenere ad Avengers: Doomsday a fine 2026, con anche tanti titoli Searchlight e 20th Century Studios nel mezzo. Ne abbiamo parlato con il direttore marketing Davide Romani.Inoltre, commentiamo il listino di I Wonder Pictures, presentato da Andrea Romeo, che include come sempre moltissimi titoli A24.Cineguru segue le Giornate Professionali di Cinema 2025 con un podcast al giorno, disponibile qui sul sito, sulle principali piattaforme di podcast e su Substack, dove potete iscrivervi alla newsletter Cineguru Intelligence. Inoltre, sul numero speciale di Fortune Italia Entertainment, distribuito in formato cartaceo alla manifestazione è disponibile un ampio approfondimento dedicato a Exhibitors Social Pulse curato da noi.

"Davide Torchia'' ospite a Rassegna Stramba.

"Rassegna Stramba" con Claudio Zuliani. Ospiti: Davide Torchia, Camillo Demichelis

"Davide Torchia'' ospite a Rassegna Stramba.

"Rassegna Stramba" con Claudio Zuliani. Ospiti: Davide Torchia, Camillo Demichelis

Empate que poderia ser vitória na Arena Corinthians passa por instante de desatenção de Léo Linck no primeiro gol e, no máximo, um centímetro que a bola permaneceu dentro de campo na jogada de origem do segundo. Mesmo assim, ponto conquistado fora de casa premia bom futebol na etapa final e mexidas certeiras de Davide. Montoro e Barrera são o futuro do Botafogo para 2026 em diante? Savarino ainda tem de onde tirar ou o ciclo caminha para o fim? É urgente buscar um novo goleiro? Rafa Barros, Jéssica Maldonado, Camilo Pinheiro Machado e Pedro Dep discutem.

IL COMMENTO ALLA TREDICESIMA GIORNATA DI SERIE A!! Al tavolo: Luca Toselli, Alessandro Iori, Edoardo Di Nuzzo e l'host Matteo Davoli.

Davide Brullo, Milo De Angelis, Nicola Crocetti"Immortale parola"Antologia della poesia italiana dalle origini ai giorni nostriCrocetti Editorewww.crocettieditore.itProprio qui, dall'energia sorgiva dei poeti, è nata la nostra lingua: dal canto di san Francesco, dalla speleologia ultramondana di Dante e dalla specola d'amore di Petrarca, dalla speculazione di Leopardi e dal genio notturno di Tasso, dall'imprecazione di Iacopone e dalla furia di Foscolo, dal dire fiabesco di Marino, dalle estasi di Ungaretti e dalle luci retrattili di Montale. Grazie ai poeti – aggraziati o feroci, dotati di una rabbia azzurra, capaci nell'impensabile – abbiamo le parole per decrittare l'anima, per appurare la profondità del nostro cuore. Senza i poeti saremmo esangui, succubi dei tempi, a servaggio delle convenzioni, mera biada dei giorni. In questa rassegna – mai tentata di tali dimensioni in un unico volume – i poeti italiani, per sempre giovani, ci prendono d'assedio: ci insegnano il coraggio, ci insidiano con gioia lunare alla gola. Un libro per la vita: dalle origini a Pasolini, i poeti che hanno reso straordinaria la storia della lingua e della letteratura italiana.Fin dalla prima antologia della nostra storia, quella di Meleagro di Gadara, la poesia rivela il suo doppio volto: storico da una parte e assoluto dall'altra. Da una parte appartiene a un foglio preciso del calendario, che la situa esattamente in quell'epoca e in quel giorno, dall'altra appartiene a un tempo selvaggio, imprendibile, che annienta ogni cronologia per diventare pura presenza. Meleagro, fedele all'etimo della parola “antologia”, chiamava l'opera di ogni poeta con il nome di un fiore e invitava segretamente i lettori a compiere un lungo viaggio nelle pianure, nelle vallate e nelle montagne per trovare il fiore più amato e contemplare la sua bellezza senza mai strapparlo al luogo in cui l'aveva visto, senza mai impedire agli altri viandanti di ammirarlo. Ebbene, gli autori di questa antologia – tre innamorati della poesia quali certamente noi siamo – hanno preso la stessa decisione: ciascuno ha scelto il proprio fiore, mostrandolo agli altri in tutto il suo splendore e lasciandolo intatto in un punto determinato del giardino storico e in un punto sconfinato del giardino senza tempo.dall'introduzione di Milo De AngelisDiventa un supporter di questo podcast: https://www.spreaker.com/podcast/il-posto-delle-parole--1487855/support.IL POSTO DELLE PAROLEascoltare fa pensarehttps://ilpostodelleparole.it/

“I happened to be visiting my family home in Italy this past week and some cows were grazing in the field opposite, regardless of the rain, fog or snow. Their bell kept me company through the week.”

Predicazione espositiva del Pastore Jonathan Whitman di Matteo capitolo 9 versetti da 27 a 34. Registrata presso il Centro Evangelico Battista di Perugia il 23 novembre 2025.Titolo del messaggio: "Chi è questo Gesù? 4 segni che Gesù è il Messia tanto atteso"MATTEO 9 V27-3427 Come Gesù partiva di là, due ciechi lo seguirono, dicendo ad alta voce: «Abbi pietà di noi, Figlio di Davide!» 28 Quando egli fu entrato nella casa, quei ciechi si avvicinarono a lui. Gesù disse loro: «Credete voi che io possa far questo?» Essi gli risposero: «Sì, Signore». 29 Allora toccò loro gli occhi dicendo: «Vi sia fatto secondo la vostra fede». 30 E gli occhi loro furono aperti. E Gesù fece loro un severo divieto, dicendo: «Guardate che nessuno lo sappia». 31 Ma quelli, usciti fuori, sparsero la fama di lui per tutto quel paese. 32 Mentre costoro uscivano, gli fu presentato un uomo muto e indemoniato. 33 Scacciato che fu il demonio, il muto parlò. E la folla si meravigliava dicendo: «Non si è mai vista una cosa simile in Israele». 34 Ma i farisei dicevano: «Egli scaccia i demòni con l'aiuto del principe dei demòni».

Vorresti ricevere notizie, saluti, auguri dalle Apostole della Vita Interiore?Lasciaci i tuoi contatti cliccando il link qui sotto e con la nostra nuova rubrica digitale potremo raggiungerti.https://www.it.apostlesofil.com/database/- Premi il tasto PLAY per ascoltare la catechesi del giorno e condividi con altri se vuoi -+ Dal Vangelo secondo Luca +Mentre Gesù si avvicinava a Gèrico, un cieco era seduto lungo la strada a mendicare. Sentendo passare la gente, domandò che cosa accadesse. Gli annunciarono: «Passa Gesù, il Nazareno!».Allora gridò dicendo: «Gesù, figlio di Davide, abbi pietà di me!». Quelli che camminavano avanti lo rimproveravano perché tacesse; ma egli gridava ancora più forte: «Figlio di Davide, abbi pietà di me!».Gesù allora si fermò e ordinò che lo conducessero da lui. Quando fu vicino, gli domandò: «Che cosa vuoi che io faccia per te?». Egli rispose: «Signore, che io veda di nuovo!». E Gesù gli disse: «Abbi di nuovo la vista! La tua fede ti ha salvato».Subito ci vide di nuovo e cominciò a seguirlo glorificando Dio. E tutto il popolo, vedendo, diede lode a Dio.Parola del Signore.

Il protagonista di questa settimana è “IL VENDITORE DI FELICITÀ”, albo illustrato. Co-protagonisti sono i suoi due autori: Davide Calí per il testo e Marco Somà per le illustrazioni. L'albo è pubblicato da Kite Edizioni.Si avvicina il Natale e questo è un albo ideale per pensare ai nostri sogni, ai desideri degli altri, alla felicità in generale. In moltissime scuole in tutta Italia questo libro è diventato uno strumento per parlare con i ragazzi di cosa significhi essere felici, ed ha dato vita a centinaia di laboratori per la costruzione dei barattoli della felicità, proprio come quelli che vende il signor piccione, il dinoccolato protagonista di questa storia.Un episodio per entrare in punta di piedi nella stagione dei sogni e dell'immaginazione. Ogni settimana una nuova storia, una nuova vita, dietro le immagini.Questo è un podcast indipendente. Clicca i link qui di seguito per: Diventare un mio PATREON e sostenere questo podcast con un piccolo contributo per coprire le spese di produzione ed aiutarmi a continuare questo progetto;Ricevere la NEWSLETTER de “Il Mondo Invisibile” in cui condivido cosa imparo ogni settimana dagli ospiti del podcast e cosa voglio ricordare per la mia pratica creativa;Ascoltare il podcast anche su YOUTUBE;Seguire l'account Instagram @ilmondoinvisibilepodcast e la pagina facebook con lo stesso nome, per vedere le opere degli artisti, e per mandarmi i tuoi commenti. A presto! Alessandro

“Picchio” arriva al PoretCast e trasforma la puntata in un viaggio tra ironia, cinema e umanità nella sua carriera. Dai premi vinti e il suo ultimo film "Il Maestro" alle trasformazioni di "Senza nessuna Pietà" e "Hammamet". Tra aneddoti, momenti comici e riflessioni profonde su arte, fallibilità e fede, Pierfrancesco Favino mostra tutto il suo talento camaleontico. Puntata powered by Illumia. Una produzione Corax. Learn more about your ad choices. Visit megaphone.fm/adchoices

Welcome to today's episode with host Sadie and a medical panel of three Hoffman Process graduates who are also esteemed medical practitioners. Our host, Sadie, Carrie Levine, Dr. David Hanscom, and Dr. Kash Trivedi engage in this powerful conversation. They cover the connection between emotional health and physical health, the mind-body connection, finding the safety within needed to heal, and so much more. With her background as a licensed Nurse Practitioner, Sadie guides the panel with insightful questions. Our guests answer through their embodied learning from both the Process and their many years of medical practice. They share insights on what it means to practice medicine with awareness, compassion, and the knowledge that can help guide their patients to deeper healing. As the conversation goes deeper into the idea of healing needing a sense of safety, Sadie then asks the panel if we each can "take responsibility for our inner experience of safety?" Carrie responds, saying, "I think we have to. I don't know that anybody else can do that for us. ... I think it's on us." We hope you enjoy this conversation with Carrie, Davide, Kash, and Sadie. Please note: While this conversation is about medicine, healing, and health, please note that what is shared here is strictly for informational purposes only and should not be considered medical advice. Please always seek the guidance of your physician or any other qualified health professional with any questions you have regarding your health or medical condition. Listen on Apple Podcasts Listen on Spotify More about Carrie E. Levine: Carrie E. Levine, CNM, IFMCP, is the founder of the Whole Woman Health clinic. She is the author of Whole Woman Health: A Guide to Creating Wellness for Any Age and Stage. A certified nurse midwife and Institute for Functional Medicine Certified Practitioner, Carrie evaluates and treats the most common women's health concerns by integrating gynecology and functional medicine. For more than two decades, Carrie has worked to help women find wholeness, connecting physical symptoms and test results with lifestyle choices and daily practices. Previously, Carrie practiced gynecology and functional medicine at the renowned Women to Women clinic in Maine (2006–2014). Before that, she provided full-scope midwifery at Miles Memorial Hospital (now Maine Health Lincoln) in Damariscotta, Maine. Patients know Carrie for her deep listening, “connecting the dots” among seemingly unrelated symptoms and emotions, and breaking personal health goals into attainable steps so clients can thrive emotionally, spiritually, and physically. Carrie earned a BS from Syracuse University. She has an RN and MSN from Case Western Reserve University. Carrie earned a Nurse-Midwifery certificate from what is now the Frontier Nursing University.  She is a member of ACNM (national and Maine chapters), the Maine Nurse Practitioners Association, and the Institute for Functional Medicine. Sign up for Carrie's free weekly newsletters featuring recipes, podcasts, articles, and more at https://carrielevine.com. Follow Carrie on Instagram, Facebook, LinkedIn, and YouTube. More about Dr. David Hanscom: David Hanscom, MD, practiced complex orthopedic spine surgery for 32 years. He quit his practice in Seattle, WA, to present his insights into solving chronic mental and physical pain. They evolved from his own 15-year battle. David escaped from the ordeal and discovered that mental pain was the biggest issue. Anxiety is the pain. His new book, Calm Your Body, Heal Your Mind: Transcend Pain, Anxiety, Anger, and Repetitive Unwanted Thoughts, is scheduled for release in June 2026. By understanding the neurophysiology driving unwanted thoughts and stimulating neuroplastic changes, they can be addressed and resolved. David's book, Back in Control: A Surgeon's Roadmap Out of Chronic Pain, systematically presents well-documented treatments for chronic pain.

The Outer Realm welcomes Reinhard Denke and E. B. David Date: November 5th, 2025 EP: 637 TOPIC: Our Guests will be discussing their book " The Orb Incident - A True Account by E.B. David The Book: In the summer of 1982, something extraordinary happened in a silent forest of upstate New York—something that would alter one man's life forever. More than four decades later, screenwriter Reinhard Denke unexpectedly uncovered a long-hidden truth when a casual acquaintance, E. B. David, shared the harrowing details of that night for the very first time. What began as a simple recollection of a strangely glowing object soon unraveled into a chilling and deeply personal account of alien contact. Through an in-depth interview filled with probing questions and startling revelations, E. B. David describes not only the encounter itself, but also the profound psychological and physical effects that have haunted—and in some cases, enlightened—him ever since. Part confessional, part investigation, this gripping narrative offers a rare, intimate glimpse into one man's extraordinary experience with the unknown—and the lasting impact it has had on his life. This is the untold story of E. B. David. And it all began with a light in the sky. Where to buy The Book: Amazon https://a.co/d/bEGzEOR Contact for the show - theouterrealmcontact@gmail.com Michelle Desrochers and The Outer Realm :https://linktr.ee/michelledesrochers_ About Our Guests: Reinhard Denke: -Reinhard Denke grew up in Texas and is a graduate of USC Film School. He got his start as a writer in 2009 with his spec script Sex, Greed, Money, Murder and Chicken Fried Steak about the Cullen Davis murders in Fort Worth, Texas. The script was chosen for the prestigious 2009 Hollywood Blacklist. In 2013, he wrote Far Below for David Oyelowo, and was hired to rewrite 2015's Captive, starring Oyelowo, Kate Mara, and Michael K. Williams. He also wrote a TV pilot and series entitled Golden Gate about 1960's era San Francisco that has been optioned by Demarest Films and wrote the limited TV series Vanished for Straight Up Films and Truly Original Entertainment. Reinhard adapted Undaunted for Rock Island Films. He wrote the screenplay Ackia for the Chickasaw Nation and award-winning director Nathan Frankowski. Also for the Chickasaw Nation, Reinhard wrote Montford; Chickasaw Rancher, which was released on Netflix in 2022. He wrote Radiant,, a bio of composer George Anthiel and movie actress Hedy Lamar. Denke also wrote Moonchild, the story of Linda Kasabian and her ordeal with the Manson Family, for director Marcus Nispel and producer Adam Krentzmann. Denke is currently working on the adaptation of H. Mitchell Caldwell's award-winning legal thriller Cost Of Arrogance. He's recently finished adapting the WWII drama Gratitude Is Not Enough by Dr. Tom Stein for producer Rick Amero and also just finished a collaboration with author Chip Jacobs adapting Jacobs' book The Darkest Glare for producer Jeff Berg. The Darkest Glare is based on a true crime case set in 1979 Los Angeles. Denke has already written three published books; "It's A Wonderful Time" and "The Inventors", part of the Hollywood Time Traveler's series. "The Orb Incident", Denke's latest book, was recently published in August of 2025. Reinhard Denke lives in Woodland Hills, California with his wife Marilee and their two dogs. E.B. David - E. B. David lives in Southern California, is married with an adult daughter, and works as a fundraiser for charitable organizations. One condition he insisted upon prior to being interviewed for the book "The Orb Incident" was that the author would not reveal anything more about his identity out of concern that efforts would be made to track him down and question him about his UFO

Davide Andrea is the author of The Electronic Connector Book and Principal of Elithion, a company that designs Battery Management System. He joins Chris to talk about the wide and wonderful world of connectors.

David E. Taylor's cult truly had it all: enslaved workers using plagiarism machines to generate AI ads to rob cancer patients, welfare fraud, and heinous sex crimes! In Part 2, we conclude his horrific story.See omnystudio.com/listener for privacy information.

In this episode of Manufacturing Hub, hosts Vladimir Romanov and Dave Griffith sit down with Davide (David) Pascucci, founder of Bright IA (https://brightiatx.com/), for an in-depth conversation about what it truly takes to build, grow, and succeed in the world of robotics integration and industrial automation.Davide shares his incredible journey from Italy's oil and gas sector to leading one of Texas's most promising automation firms. His story highlights the reality of moving from traditional controls work to full-scale robotics integration. Listeners will learn how his company evolved from small local projects into complex manufacturing solutions involving welding cells, painting robots, and palletizing systems used across multiple industries including food and beverage, fabrication, and renewables.The discussion explores how system integrators can strategically position themselves in the modern automation ecosystem. Davide explains the importance of vendor relationships, revealing how open collaboration with companies like Fanuc and KUKA helped his firm grow while avoiding common pitfalls faced by new integrators. He provides practical insights into how to evaluate robot brands, manage the mechanical design and safety aspects of projects, and find the right balance between in-house engineering and subcontracting work.Listeners will also hear a detailed perspective on the Texas manufacturing landscape, where oil and gas still dominate but are now accompanied by a new wave of innovation from defense, aerospace, semiconductor, and AI-driven industries. Davide explains how these shifts are creating a demand for flexible automation and robotics expertise across the region.A large portion of the conversation focuses on the real-world challenges that come with integrating robots on the factory floor. Davide talks about dealing with customers who insist on collaborative robots when industrial robots are better suited for the job. He describes how simulation and digital twin tools can help demonstrate cycle times and prove system capabilities before implementation. His transparency about pricing, quoting, and project management makes this a must-listen episode for anyone looking to understand the business side of integration, not just the technical aspects.The episode also explores how smaller robotics firms can collaborate with European and Asian OEMs that are entering the North American market. Davide shares the lessons he learned when working with foreign manufacturers, emphasizing that support, spare parts, and local presence are often more valuable than price alone. His advice is invaluable for early-stage integrators trying to evaluate new partnerships or decide which technologies to adopt.As the conversation continues, Davide, Vlad, and Dave discuss what the future holds for robotics integration. Davide predicts an explosion of applications over the next few years, driven by manufacturing reshoring, labor shortages, and advancements in AI and simulation. He believes that companies who fail to automate will simply be left behind. His message to manufacturers is clear: whether you like it or not, automation will be necessary to stay competitive.Listeners will also appreciate Davide's insights into workforce development and training. He believes that plant operators and technicians must reskill to remain relevant in a world where machines are becoming smarter and more autonomous. He shares inspiring stories of training shop floor workers to operate robots with confidence and how empowering end users ultimately makes integration projects more successful and sustainable.Toward the end of the episode, the group reflects on what it means to build a modern systems integration business. Davide shares lessons on quoting, scaling a team, developing repeatable processes, and thinking strategically about products versus projects. His perspective highlights the difference between being a contractor and building a true business that can scale and create long-term value.Finally, the conversation closes with book recommendations that have shaped Davide's thinking, including Extreme Ownership by Jocko Willink, Buy Back Your Time by Dan Martell, and of course, the timeless lessons found in The Bible. These selections capture the mindset of a leader who believes in responsibility, efficiency, and personal growth.If you are an engineer, systems integrator, plant manager, or decision-maker in manufacturing, this episode will give you a firsthand look into the future of robotics integration. It will help you understand how to evaluate partners, manage projects, and prepare your organization for the next generation of automation.Timestamps00:00 Introduction and overview of the Systems Integrator theme 03:00 Davide's journey from Italy to Texas and his shift from oil and gas to robotics 06:00 How Automation Stars of Texas was created and what the event represents 07:30 The Texas manufacturing ecosystem and opportunities in automation 10:00 Transitioning from traditional controls work to robotics integration 12:00 The learning curve of programming robots and managing motion systems 16:00 Deciding when to specialize versus subcontracting mechanical and electrical work 19:00 Lessons from growing Bright IA and balancing costs, scope, and risk 21:00 Building strong relationships with robot manufacturers such as Fanuc and KUKA 26:00 The importance of vendor support and collaboration for small integrators 29:00 Managing CAD and mechanical design in robotics projects 33:00 The reality of collaborative robots compared to industrial robots 36:00 Evaluating low-cost robotic arms and the trade-offs of price versus support 41:00 How simulation and digital twins improve quoting and validation 48:00 Why some robotics projects fail and how to recover or redesign them 52:00 Working with European and Asian OEMs and lessons in market adaptation 58:00 Advice for new integrators on partnerships, quoting, and strategy 01:04:00 Predicting the future of robotics and automation in the next three years 01:07:00 Career advice for engineers looking to transition into robotics 01:11:00 Book recommendations and leadership lessons 01:13:00 Davide's vision for new robotic product development and AI applicationsBooks Mentioned Extreme Ownership – Jocko Willink and Leif Babin Buy Back Your Time – Dan Martell The BibleGuest Davide (David) Pascucci Founder and President, Bright IA Website: https://brightiatx.com/ LinkedIn: https://www.linkedin.com/in/davidepascucci/Bright IA is an automation and robotics integration firm based in Texas, providing complete engineering solutions for manufacturing environments, including welding systems, palletizing, safety integration, and industrial control design.Hosts Vladimir Romanov – Founder of Joltek (https://www.joltek.com), Electrical Engineer, Consultant, and Co-Host of Manufacturing Hub Dave Griffith – Founder of Dave Griffith C...

Dr. Pippa Malmgren joins host Rose Claverie on the Harvest Series Podcast for a sweeping conversation on technology, geopolitics, and what it means to be human in an age of exponential change. From quantum chips to the emotional intelligence revolution, Malmgren reveals how we might escape scarcity thinking and embrace a future defined by empathy and abundance.Recorded in Kaplankaya, Türkiye, this episode journeys through the corridors of power, the illusions of conflict, and the surprising promise of prosperity for all.You can follow us on Instagram at @HarvestSeries or @rose.claverie for updates.Watch our podcast episodes and speaker sessions on YouTube: Harvest Series.Credits:Sound editing by: @lesbellesfrequencesTechnician in Kaplankaya: Joel MoriasiMusic by: ChambordArtwork by: Davide d'AntonioHarvest Series is produced in partnership with Athena Advisers and Capital PartnersHarvest Series Founders: Burak Öymen and Roman Carel

Robert sits down with Jake Hanrahan to discuss the recently busted cult / call center of Bishop David Taylor's, Jesus Christ's Best Friend. (2 Part Series) Check out Sad Oligarch - https://open.spotify.com/show/5n4CUGYYZ4fc4L5yWYX7gK https://podcasts.apple.com/us/podcast/sad-oligarch/id1691403387 https://www.iheart.com/podcast/1119-sad-oligarch-116754842/episode/a-family-annihilation-in-moscow-117331449/ See omnystudio.com/listener for privacy information.

What if the thing you're resisting is the very thing that changes your life? In this episode, I sit down with Davide “Davi” De Pierro, an attorney who went from chronically offline to a viral TikTok and Instagram creator with over 4 million followers in six months. Davi shares why action before certainty is the only way to build confidence, and the creative principles that make content resonate. Get ready to learn how to act before you're ready, stay authentic, and reinvent yourself without waiting for permission. In This Episode You Will Learn How to START BEFORE YOU'RE READY. Ways to create AUTHENTIC CONTENT. How to use VULNERABILITY as a storytelling tool without losing privacy. The difference between ENTERTAINING and TEACHING when building an audience. How to shift from a FIXED IDENTITY to a MULTIFACETED SELF. MINDSET PRACTICES to turn fear into fuel for reinvention. Resources + Links Get Davide's Audio Book “The Letters I Never Sent” HERE Sign up for a one-dollar-per-month trial period at shopify.com/monahan Download the CFO's Guide to AI and Machine Learning at NetSuite.com/MONAHAN. Want to do more and spend less like Uber, 8x8, and Databricks Mosaic? Take a free test drive of OCI at oracle.com/MONAHAN. Get 10% off your first Mitopure order at timeline.com/CONFIDENCE. Get 15% off your first order when you use code CONFIDENCE15 at checkout at jennikayne.com. Call my digital clone at 201-897-2553!  Visit heathermonahan.com Sign up for my mailing list: heathermonahan.com/mailing-list/  Overcome Your Villains is Available NOW! Order here: https://overcomeyourvillains.com  If you haven't yet, get my first book Confidence Creator Follow Heather on Instagram & LinkedIn Davide on Instagram & TikTok

Who are you standing in the gap for? Discover the power of intercessory prayer to transform lives, churches, and communities, and how you can join Jesus, the ultimate Intercessor, in this life-saving work.

Anche se arrivato Down Under con la residenza già acquisita, la vita australiana di Davide Rigo è iniziata con difficoltà lavorative inattese.

I sit down with the internet's favorite guy in his car, Davide De Pierro. We discuss what is wrong with the current state of dating right now, why more religious couples stay together, how honest we should be during the dating process, why he's not on the apps, what he wishes he knew in his 20s, what he is looking for when dating now, and so much more.Get More We Met At Acme!Youtube: @wemetatacmeIG: @lindzmetz @wemetatacme @wemetatbabySubstack: @wemetatacme + @wemetatbabyWebsite: @wemetatacmeSponsors:Head to coterie.com and use code ACME20 at checkout for 20% off your first order.Give yourself the luxury you deserve with Quince! Go to quince.com/acme for free shipping on your order and 365-day returns.Start paying rent through Bilt and take advantage of your Neighborhood Benefits by going to joinbilt.com/acmeWinx Health is now nationwide at Walgreens! Visit hellowinx.com/acme for 25% off.Chapters:06:17 Journey into Social Media and Dating Insights30:45 Setting Boundaries in Relationships33:09 The Future of Dating36:21 Challenging Romantic Beliefs43:30 Navigating Modern DatingProduced by Dear Media.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

hi! here's a cutie lil solo giving you an update on life stuff including Baroncini Import, and how i deal with personal stuff that's super hard. i also answer some of your questions about work life balance (making sure Davide gets a nap) and more!Produced by Dear MediaSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

It's iFanboy 20/25 -- 20 years of podcasting and 25 years of iFanboy! These Jamokes got frickin' cats in their pockets! Silence pervades, and is lauded for it. We attempt to solve both the Alpha and Omega, which mostly results in a really tall Darkseid. But if you just apply the Supergods rule, it's all good. Note: Time codes are estimates due to dynamic ad insertion by the distributor. Running Time: 01:23:30 Pick of the Week:00:01:50 - G.I. Joe: A Real American Hero #321 Comics:00:12:46 - DC K.O. #100:18:29 - Marvel Knights: The Punisher #100:24:30 - The Avengers #787 (31)00:33:14 - Death to Pachuco #100:37:27 - Transformers #2500:41:24 - Farmhand #2600:46:53 - Batman: The Long Halloween - The Last Halloween #900:49:08 - Red Book #1 Patron Pick:00:53:14 - Conan the Barbarian #25 Patron Thanks:01:03:49 - Todd Listener Mail:01:07:16 - David E. from San Francisco, California asks whether DC or Marvel is currently boasting the best stable of artists.01:13:37 - Greag B. from Ann Arbor, Michigan asks who loses. Tom King or Jonathan Hickman? So we work with that. Brought To You By: Found Banking – This episode is sponsored by Found Banking. Join the thousands of small business owners who have streamlined their finances. iFanboy Patrons – Become one today for as little as $3/month! Or join for a full year and get a discount! You can also make a one time donation of any amount! iFanboy T-Shirts and Merch – Show your iFanboy pride with a t-shirt or other great merchandise on Threadless! We've got TWENTY THREE designs! Music:“Enjoy the Silence”No Use for a Name Learn more about your ad choices. Visit megaphone.fm/adchoices